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Abstract
In a case-control study aimed at localizing disease variants, association between a marker
and the disease status is often tested by comparing the marker allele frequencies among cases
and controls. These marker allele frequencies are expected to be different if the marker is
associated with the disease. The power of the commonly used allele based test is based on
the marker allele frequency; markers with a low minor allele frequency have less power to
be detected (if they are associated with the disease), than markers with high minor allele
frequency. Therefore the strategy of selecting markers for follow-up study based on their
p-values, favors markers with a high minor allele frequency.
We propose an allele based test that does not have this (unwanted) property and is there-
fore more powerful for markers with a low minor allele frequency. This test may, therefore,
be more effective when searching for rare causal variants. The asymptotic power function of
the test is derived and simulation studies are performed for finite sample properties of the
test. Next, the existing and the proposed tests are applied to data; this is not included yet.
In the light of the current interest in detecting association between complex phenotypes
and causal variants with a low minor allele frequencies, this test is expected to be of relevance.
Case-control study, allele based test, linkage disequilibrium (LD), power, p-values, minor allele
frequency (MAF)
1
ar
X
iv
:1
50
9.
06
13
2v
1 
 [s
tat
.M
E]
  2
1 S
ep
 20
15
1 Introduction
To locate disease variants and dichotomous trait loci, association studies of genetic markers are
often conducted with a case-control design. Several genetic association tests have been proposed
(see e.g. [2, 15]). One simple and perhaps one of the most natural test, is the singular marker
allele based test that is based on the difference of the sample marker allele frequencies in cases
and controls.
A marker is associated with the disease or trait if it is in linkage disequilibrium (LD) with
one of the causal variants (see e.g. [15]). On average, the larger the degree of LD, the smaller
the p-value of the association test. However, the p-value obtained with the (commonly used)
singular marker allele based test is also a function of the marker allele frequency; markers with
high minor allele frequencies (MAFs) have more power to be detected than markers with low
MAFs. The strategy of selecting interesting markers for follow-up study based on their p-values
only, is therefore biased towards markers with high MAFs.
Several other strategies for prioritizing the markers for follow-up studies have been proposed
and compared, like ranking markers based on the Bayes Factor signal ([12, 13]), the likelihood
ratio signal ([9]), frequentist factor signal ([11]), and PrPES signals ([8]). [9] compared these
strategies, including ranking markers based on the p-values of the allele based test and Cochran-
Armitage-trend test, by applying them to two data-sets. The markers with the smallest p-values
obtained from the allele based test are also top-ranked by the other methods. Some strategies
down-weight markers with small MAF even more than the allele based test does.
In this paper we propose an allele based test for testing association in case-control studies
that does not favor markers with high minor allele frequencies. It is shown that the test has
more power than the commonly used allele based test if the minor allele frequency of the marker
is quite low. The proposed test-statistic is found by standardizing the difference of sample allele
frequencies in a different way than the commonly allele based test does. An explicit asymptotic
power function is derived and finite sample properties are obtained by simulation studies. The
test will be applied to data.
“Missing” heritability refers to the fact that for many traits, only a small proportion of the
variability in the population can be explained by causal variants that have been identified up
to now (see e.g. [5]). One possible explanation for this “missing” heritability is the presence
of low-frequency variants of relatively strong effect on disease risk. Indeed, rare variants found
by resequencing have already been described to affect complex diseases ([7]). In the light of
the current interest in detecting association between complex phenotypes and low-frequency
variants and localizing causal variants with small minor allele frequencies, the implications of
the present paper are expected to be of relevance.
2 Methods
2.1 Setting
The case-control status for a random individual in the general population is denoted by X,
X = 1 for a case and X = 0 for a control. The fractions of cases and controls in the total
population are denoted by pi = P(X = 1) and 1 − pi = P(X = 0). There may be multiple
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causal variants; the aim in association studies is to locate these variants. We initially assume
that any given marker is in linkage disequilibrium with at most one causal variant. Therefore,
it is sufficient to consider the situation where there is only one causal variant. Suppose the
causal variant is biallelic with alleles A1 and A2 and with corresponding allele frequencies p1
and p2 = 1 − p1 in the total population. In case the causal variant is not biallelic, the second
allele, A2, could be regarded as all alleles which are not the A1-allele. We denote the fraction
of individuals with the disease (X = 1) among those individuals with genotype (Ai, Aj) at the
causal variant by piij = P(X = 1|AiAj) for i, j = 1, 2 and we assume that pi12 = pi21.
We consider a biallelic marker which may or may not be in proximity with the causal variant.
One of the marker alleles is denoted as M1 and the other allele as M2. The allele frequencies
for M1 and M2 in the general population are denoted as q1 and q2 = 1 − q1 and the Mi allele
frequencies among the controls and cases are denoted as qi|0 = qi|X=0 and qi|1 = qi|X=1 for
i = 1, 2.
A common measure for the degree of LD between a marker and a causal variant is given
by the quantity ∆ij = Dij/
√
p1p2q1q2, with Dij = P(AiMj) − piqj where P(AiMj) is the
(Ai,Mj) haplotype-frequency in the total population (see for instance [3]). By definition ∆ij =
cor(1Ai , 1Mj ) with, for a randomly chosen haplotype, 1Ai and 1Mj the indicator functions which
equal 1 if the causal variant is Ai and 0 otherwise, and similar for the marker allele Mj . In the
Appendix A in the Supplementary Material it is derived that
q1|0 − q1|1√
q1q2
= ∆
p1|0 − p1|1√
p1p2
(1)
with ∆ = ∆11. So, the relative difference between the allele frequencies among the controls and
cases at the causal variant (the quotient on the right hand side of the expression) is passed on
to the neighboring markers by multiplying this relative difference by ∆, the degree of linkage
disequilibrium between the alleles at the marker and the causal variant. From this formula it
can be directly seen that the M1 allele frequencies among the controls and cases equal if the
marker is in linkage equilibrium with the causal variant, i.e. ∆ = 0.
In order to find markers that are associated with the disease or, actually, are in linkage
disequilibrium with the causal variant, case-control data is collected. Suppose we have a sample
of R individuals from the cases and S individuals from the controls; R and S are fixed and
non-random. Their sum is denoted as N = S +R. Since every genotype consists of two alleles,
there are actually 2R and 2S alleles from the cases and controls, respectively. The number
of M1 alleles among the cases and controls are denoted as R1 and S1, respectively. For the
number of M2 alleles, the notation is analogues: R2 and S2 for the cases and controls. Note
that R1 +R2 = 2R and S1 +S2 = 2S. Based on these data the fraction of M1 alleles among the
controls and the cases can be estimated as qˆ1|0 = S1/(2S) and qˆ1|1 = R1/(2R).
In the following two allele based association tests are described for testing the null hypothesis
H0 : q1|0 = q1|1 against the alternative H1 : q1|0 6= q1|1. The first test we describe, is the
commonly used test. This test is based on the difference qˆ1|0 − qˆ1|1, standardized so that the
test-statistic is asymptotically standard normal distributed under the null hypothesis of no
association. Calculations will show that by the way of standardizing, markers with a low minor
allele frequency have less power to be detected under the alternative hypothesis, than markers
with a high minor allele frequency. The test we propose is also based on the difference qˆ1|0− qˆ1|1,
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but standardized in a different way. In Section 3 the power of the two tests are compared.
2.2 Commonly used allele based association test
The commonly used allele based test-statistic for testing the null hypothesis H0 : q1|0 = q1|1
against H1 : q1|0 6= q1|1 is given by
T =
qˆ1|0 − qˆ1|1√
Vˆ
with qˆ1|0 = S1/(2S) and qˆ1|1 = R1/(2R). Furthermore, Vˆ is an estimator of the variance
V = Var (qˆ1|0 − qˆ1|1) = V0 + V1, with V0 and V1 defined as
V0 = Var qˆ1|0 =
q1|0(1− q1|0)
2S
V1 = Var qˆ1|1 =
q1|1(1− q1|1)
2R
. (2)
The unknown frequencies q1|0 and q1|1 in V0 and V1 are, usually, estimated by qˆ1|0 and qˆ1|1, so
that V is asymptotically unbiased under the null and alternative hypothesis. For λ = R/N the
fraction of sampled cases, the variance V equals
V = V0 + V1 =
λq1|0q2|0 + (1− λ)q1|1q2|1
2Nλ(1− λ) = m
−1(λq1|0q2|0 + (1− λ)q1|1q2|1)
for m = 2Nλ(1 − λ). For large sample sizes, the test-statistic T has, approximately, a normal
distribution with mean
√
m
q1|0 − q1|1√
λq1|0q2|0 + (1− λ)q1|1q2|1
=
√
mQB∆ (3)
and variance 1, where
B =
p1|0 − p1|1√
p1p2
and Q2 =
q1q2
λq1|0q2|0 + (1− λ)q1|1q2|1
. (4)
The equality in (3) follows from (1). Under the null hypothesis that q1|0 = q1|1 (i.e. ∆ = 0), T
has, asymptotically, a standard normal distribution, whence H0 is rejected for |T | ≥ zα/2, with
zα/2 the upper-α/2-quantile of the standard normal distribution. The two-sided power-function
of the test (approximately) equals, for large sample sizes,
P(|T | ≥ zα/2) = 1− Φ(zα/2 −
√
mB∆Q) + Φ(−zα/2 −
√
mB∆Q). (5)
The power of the test is controlled by the product
√
mB∆Q. The first term,
√
m, is specific for
the way of sampling and is, therefore, equal for every marker. The second term, B, is specific
for the causal variant and is equal for all markers that are in linkage disequilibrium with the
same causal variant. The third term, ∆, measures the degree of LD between the marker and the
causal variant and its value varies over the markers. The last term, Q, depends on the marker.
Under the null hypothesis that a marker is not associated with the disease Q = 1, but under
the alternative Q is either smaller or larger than 1, depending on the (conditional) marker allele
frequencies. That means that the markers in the association study are weighted; markers with
Q > 1 do get more power to be detected than markers with Q < 1.
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2.3 Allele based test for markers with low MAF
Define the test-statistic
W =
√
m
qˆ1|0 − qˆ1|1√
qˆ1qˆ2
(6)
with m = 2Nλ(1−λ) (as before) and qˆ1 = pˆiqˆ1|1 + (1− pˆi)qˆ1|0 and qˆ2 = pˆiqˆ2|1 + (1− pˆi)qˆ2|0, where
pˆi is an estimate of the disease prevalence P(X = 1). This estimate cannot be obtained from
the samples of cases and controls, but should be estimated based on external data. For many
diseases, an estimate of the population prevalence pi is available, for instance in the literature
or in national registries.
The test-statistics W and T are related via the relationship W = TQˆ−1, with Qˆ an estimate
of Q in (4); it is found by inserting the estimates qˆ1 and qˆ2 (as just defined) and the marker
sample frequencies among cases and controls. By the law of large numbers, Qˆ approximately
equals Q for large samples and from Slutsky’s lemma and the continuous mapping theorem (see
e.g. [10]) it follows that W has, approximately, a normal distribution with mean
√
m
q1|0 − q1|1√
q1q2
=
√
mB∆,
and variance Q−2. Under the null hypothesis, q1|0 = q1|1,∆ = 0 and Q = 1 and W has,
asymptotically, a standard normal distribution, whence H0 is rejected for |W | ≥ zα/2 for zα/2
the upper α quantile of the standard normal distribution. Under the null hypothesis qˆ1 =
pˆiq1|1 + (1 − pˆi)q1|0 ≈ pˆiq1 + (1 − pˆi)q1 = q1, no matter the value of pˆi. That means that, even
if the estimate of pi is far away from the true value, the type I error of the test will still be
approximately correct if the sample sizes are large enough. The two-sided power function for W
is given by
P(|W | > zα/2) ≈ P(|T | > zα/2Q)
= 1− Φ(zα/2Q−
√
mB∆Q) + Φ(−zα/2Q−
√
mB∆Q). (7)
The power functions for W and T are very similar, but differ in the way Q is the expression.
In the power function for W , also the quantile zα/2 is multiplied with Q. If Q = 1 (i.e. under
H0) the power functions equal (to α). Under the alternative hypothesis either Q > 1 or Q < 1.
If the sample size is large, this will probably also hold for Qˆ (since Qˆ converges in probability
to Q if also pˆi converges in probability to pi). From the definitions of T and W , it follows that
|W | > |T | if Qˆ < 1 and |W | < |T | if Qˆ > 1; if Qˆ < 1 the test based on W is more powerful,
whereas the test based on T is more powerful if Qˆ > 1.
In Appendix B in the Supplementary Materials it is shown that, if M1 is positively correlated
with the risk allele (A1 or A2) and q1 is sufficiently small, Q will be smaller than 1. However, if
M1 is negatively correlated with the risk allele, Q > 1. If the risk allele is the minor allele and
q1 is small, strong negative correlation with the risk allele are not possible within the parameter
space of the genetic model. The latter can be easily seen from the following. Remind that
∆ = (P(A1,M1) − p1q1)/√p1p2q1q2. Consequently, ∆ ≥ −p1q1/√p1p2q1q2. If p1 = q1 = 0.05,
∆ > −0.053, and p1 = 0.25, q1 = 0.05 yields ∆ > −0.12 and p1 = q1 = 0.25, yields ∆ > −0.26.
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2.4 Generalization of the test-statistic: Wδ
The test-statistic W can be generalized by allowing other values in stead of pi. Define the
test-statistic
Wδ =
√
m(qˆ1|0 − qˆ1|1)√
(δqˆ1|1 + (1− δ)qˆ1|0)(δqˆ2|1 + (1− δ)qˆ2|0)
. (8)
For δ = pˆi, this statistic Wpˆi equals W and, furthermore, Wδ = TQˆ
−1
δ with Qˆδ an estimate for
Qδ with Q
2
δ = q1q2/(δq1|0q2|0 + (1 − δ)q1|1q2|1) (similar to Q2 as defined before). The estimate
of Qδ is found by inserting estimates of the allele frequencies, like is done for Q.
Under the null hypothesis that q1|0 = q1|1 and the denominator of Wδ converges in probability
to
√
q1q2, notwithstanding the value of δ. That means that under the null hypothesis, the test-
statistic Wδ has, approximately, a standard normal distribution, for large sample sizes. So, the
null hypothesis of no association is rejected if |Wδ| > zα/2.
If δ = pi, the denominator converges to
√
q1q2 under the alternative hypothesis. So, only in
that case the mean of the test-statistic approximates
√
mB∆ for large sample sizes. The test
is most powerful if, under the alternative hypothesis, the denominator is minimized. If M1 is
the minor allele and positively correlated with the disease and, thus q1|0 < q1|1 < 0.5, the test
is optimal for δ = 0 and least optimal for δ = 1. If 0.5 > q1|0 > q1|1 (the minor allele M1 is
negatively correlated with the disease), it is the other way around. For 0 < δ < 1, the power is
in between the minimum and maximum. In practice it is unknown whether the minor allele M1
is positively or negatively correlated with the disease.
2.5 Combined test of W and T
The two test-statistics W and T are linked via T = WQˆ. If Qˆ > 1, the test with test-statistic T
is more powerful, whereas the opposite holds if Qˆ < 1. If Qˆ = 1 then T = W and the two tests
are equivalent. To have best of both of tests, the two tests could be combined. Define
U = T1Qˆ>1 +W1Qˆ≤1 = WQˆ1Qˆ>1 +W1Qˆ≤1 (9)
as the combined test-statistic. By combining the law of large numbers, Slutsky’s lemma and the
continuous mapping theorem (see e.g. [10]), U has asymptotically a standard normal distribution
under the null hypothesis of no association; the null hypothesis is rejected for |U | ≥ zα/2. The
asymptotic power function for U equals the one of W if Q < 1 and of T if Q > 1.
In a similar way the test-statistics Wδ and T could be combined.
2.6 Multiple causal variants
Suppose there are multiple causal variants, but every marker is in linkage disequilibrium with
at most one causal variant. The value of B is specific for the causal variant and will, therefore,
be the same for all markers which are in linkage disequilibrium with this causal variant. Since
the power function (and the p-value) depends on the value of B, markers can only be ranked on
their p-values locally; for all markers which are in linkage disequilibrium with the same causal
variant. In practice it is unknown whether there is only one or multiple causal variants. One
should be careful when comparing p-values for markers at different chromosomes or located far
apart.
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2.7 Measuring the effect size
For the markers that show significant association with the disease status, the effect size is of
interest. When testing based on the test-statistics T or W , the difference between the allele
frequencies among cases and controls, q1|0 − q1|1, could be used as a measure of effect, but this
difference is difficult to interpret. In practice the Cochran-Armitage test or the test-statistic T ,
is often used for testing association, whereas an effect size in terms of odds ratios is estimated by
fitting a logistic regression model ([14]). It would be more natural to use the same statistic for
testing association and estimating an effect size. This can be done within a logistic regression
model, but also based on the test-statistics W or T . The effect size defined as
P(X = 0|M1)
P(X = 1|M1)
/
P(X = 0)
P(X = 1)
,
can be estimated and a corresponding confidence interval can be constructed. This can be seen
by writing this fraction as (using Bayes theorem) q1|0/q1|1 = 1 + (q1|0 − q1|1)/q1|1 and noting
that qˆ1|1 is consistent by the law of large numbers. This quantity is not based on any model
assumptions, like in a logistic regression model, and is therefore very appropriate for quantifying
the marker effect size.
When determining a quantity for measuring an effect size, it is important to keep in mind
what the aim of the study is. In case one aims to estimate the disease risk based on the observed
genotypes at markers which are possibly not the causal variant, odds ratios for different markers
would be appropriate. However, in case one aims to find the causal variant, one may prefer to
use a measure that tries to quantify the distance between markers and a causal variant, or at
least orders the markers with respect to their distance to the causal variant. Of course, it is not
possible to measure the physical distance between markers and a causal variant, but, locally,
the markers can be ordered with respect to the degree of linkage disequilibrium with a causal
variant. In the previous subsection we have seen that W/
√
m ≈ B∆, where B is equal for all
markers that are in LD with the same causal variant. That means that ranking the markers (in
a small region of the chromosome) based on the test-statistic |W |, is equivalent to ranking them
based on (an estimate of) the degree the marker is in LD with the causal variant (∆). Although,
it is known that ∆ between markers and a causal variant is not necessarily a monotone function
with the physical distance between the two, it is expected that there is a positive relationship
and the causal variant will be located nearby the markers which are strongest in LD with the
causal variant.
3 Results
This section is divided into two subsections. In the first subsection the asymptotic power func-
tions of the two tests are compared. In practice, the sample sizes are finite. In the second
subsection we perform simulation to study the type I error for finite samples, and the effect of
the extra variability due to the fact that pi is estimated.
7
3.1 Comparison of the asymptotic power functions
We define the A1-allele at the causal variant as the high risk allele and the disease probabilities
are taken equal to pi11 = 0.60, pi22 = 0.10 and for the additive model pi12 = (pi11 +pi22)/2 = 0.35.
In Figure 1 the asymptotic power function is given as a function of q1 (first and second plot)
and of ∆ (third plot). In all cases R = S = 1000 and α = 1.0e−8. In the first plot p1 = 0.05 and
p1 = 0.15 in the second plot. In both cases ∆ = 0.3. The power function for the test-statistic
W is plotted as a continuous line and for T as a dashed line. In the most right plot in Figure 1,
the power function as a function of ∆ is given. Now, p1 = 0.05 and q1 equals either p1 or 3p1.
Again, the dashed lines represent the power for the test with test-statistic T (q1 = p1 lower line,
q1 = 3p1 upper line) and the continuous lines for the test with test-statistic W (the two lines
overlap). For all plots we inserted the true value of pi in the power function, because it will be
shown below that the power function is robust against misspecification of the parameter pi.
From the plots it can be concluded that the test based on test-statistic W is more powerful
than the one based on T for the genetic models described above. The power based on W is
approximately constant as a function of q1, whereas the power based on T increases with q1. So,
W does not, a-priori, favors markers with a large minor allele frequency. This makes the p-values
comparable across markers. This does not hold for T . The power functions were plotted for
more genetic models, including the dominant and the recessive model. As long as the correlation
between A1 and M1 is positive, the conclusions remain the same.
If the minor allele M1 is negatively correlated with the causal allele A1, the theory tells us
that the test based on T is more powerful. We consider the same setting as before. In the left
plot of Figure 2 the power functions for the two tests are given as a function of q1 for ∆ = −0.40
and p1 = 0.60. The power of the test based on T is indeed higher. However, note the low power
of both tests. In the right plot of Figure 2 the power is plotted as a function of ∆. Again, the
test T is more powerful if ∆ < 0.
Misclassification of pi
The denominator of the test-statistic W contains the parameter pi, the prevalence of the disease,
which cannot be estimated from the case-control data itself, but has to be estimated based on
data from a different source. Misspecification of this parameter affects the power of the test.
Therefore, the power function is considered for different values of the estimate pˆi. So, actually
the power of the test based on Wδ is considered for different values for δ near pi. That means
that misclassification of pi will never lead to a test with inflated type I error (if the sample size
is big enough), but to a different test which has a priori a slight preference for markers with
either small (if pˆi < pi) or large (if pˆi > pi) minor allele frequencies.
The power function was computed for exactly the same models as was done before. The
results are given in Figure 3. The power was computed for pˆi = 0.2 (lowest continuous lines)
pˆi = pi = 0.125 (continuous line in the middle), pˆi = 0.075 (upper line). Since the power function
for T does not contain pi, only one curve is found; the dashed line. More models were considered.
In all cases similar results were obtained. We conclude that allele based test for testing with the
test-statistic W is robust against small misspecification of pi.
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Figure 1: Power functions for T (dashed lines) and W (continuous lines). Additive model with:
pi11 = 0.60, pi22 = 0.10 and pi12 = 0.35.
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Figure 2: Power functions for T (dashed lines) and W (continuous lines) in the additive model
with, left ∆ = −0.40.
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Power of Wδ
In the previous paragraph we considered the effect of small deviations of δ near pi on the power
of Wδ. In this paragraph, we consider what happens if δ runs from 0 to 1. In the Figure 4 the
asymptotic power of Wδ is plotted as a function of q1, for different values of δ. The fat line
(third line from above) indicates the power function for W = Wpi with pi = 0.125, and the thin
continuous lines for different values of δ (δ = 0, 0.1, . . . , 0.9, 1.0, from upper to lowest line). It
can be seen that only for δ ≈ pi the lines are more or less constant; the power is not affected by
the marker allele frequency. Above the fat line, the power functions are slightly decreasing as a
function of q1, and below the fat line, the power is increasing.
3.2 Finite samples
The power function and the computation of p-values are based on asymptotic normality of the
test-statistic W . In practice the sample sizes are finite and not infinite. Therefore the normality
approximation may not be exact and a continuity correction may improve this approximation.
A correction can be done in multiple ways. We used the following:
Wcor =
√
m
qˆ1|0 − qˆ1|1 ± 12 min{S,R}/(2SR)√
qˆ1qˆ2
, (10)
where the “maximum” could be replaced by the “minimum” if one prefers to correct less. The
null distribution of the test-statistic is asymptotically standard normal. In practice the number
of observations is not infinite and the finite sample distribution may be different from the
asymptotic distribution. We performed a simulation study to check the type I error for the
three tests. Like before we take p1 = 0.10, pi11 = 0.60 and pi22 = 0.10 in the additive model.
Since we do the simulation under the null hypothesis ∆ = 0. We simulate 100,000,000 times
R cases and S controls from the model given in Table 1, compute the test-statistic T,W and
Wcor, the corresponding p-values, and compute an estimate of the type I error as the fraction
of p-values smaller than α. The results are given in Table 1.
From the table it can be seen that the type I error for the test based on W is slightly inflated
especially if the sample sizes are small and the maf of the marker is low. This inflation disappears
if the sample size or the maf grows. After continuity correction as described in (10) there seems
to be still an inflation, but this is smaller already.
In the previous example the value of pi is 0.15. If the prevalence of the disease in the
population is lower, the sample size is small (around 500 cases and 500 controls) and the MAF
of the marker is also quite low (0.10 or lower), the type I error inflation may become unacceptable.
In that case one could decide to insert a higher value of δ, what diminish the type I error, but
decreases the power of test under the alternative hypothesis.
We also performed several simulation studies under the alternative hypothesis. In all cases
the power functions based on finite samples were very similar to the asymptotic power function
(results not shown).
Combined Test
We perform several simulation studies to study the performance of the combined test with test-
statistic U . The results are as expected. For large sample sizes the null distribution is close
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Figure 3: Power function based on statistic W as a function of q1 for different values of pi. From
lowest continuous line to most upper line: pˆi = 0.20, pˆi = pi, and pˆi = 0.075. The dashed lines
gives the power for the test based on test-statistic T .
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Figure 4: Power function based on statistic Wδ as a function of q1 for different values of δ.
Dashed lines: power based on T . Fat line (third lines from above): power based on W = Wpi.
The other lines are the power functions based on Wδ for δ = 0, 0.1, . . . , 0.9, 1.0, from upper to
lowest line.
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q1 = 0.10 q1 = 0.25
α 1× 10−3 1× 10−4 1× 10−5 1× 10−3 1× 10−4 1× 10−5
test ×10−3 ×10−4 ×10−5 ×10−3 ×10−4 ×10−5
R = S = 500
T 1.00124 0.9698 1.006 1.02640 1.0378 1.118
δ = pi Wcor 1.12314 1.5258 2.324 0.97097 1.0419 1.175
W 1.27542 1.7627 2.786 1.06058 1.1574 1.300
δ = 0.20 Wcor,δ 1.04681 1.3322 1.893 0.95332 0.9981 1.111
Wδ 1.19209 1.5282 2.145 1.04465 1.1069 1.229
δ = 0.30 Wcor,δ 0.93276 1.0104 1.226 0.92657 0.9375 0.969
Wδ 1.06701 1.1830 1.451 1.01572 1.0387 1.100
δ = 0.40 Wcor,δ 0.87548 0.8479 0.899 0.91026 0.8918 0.922
Wδ 1.00305 0.9801 1.040 0.99397 0.9995 1.027
R = S = 1000
T 1.00363 0.9930 1.023 1.02000 1.0359 1.005
δ = pi Wcor 1.03673 1.2424 1.659 0.96959 1.0172 1.059
W 1.12922 1.3821 1.845 1.03510 1.0996 1.155
δ = 0.20 Wcor,δ 1.00093 1.1403 1.433 0.96411 0.9991 1.010
Wδ 1.09388 1.2723 1.607 1.02742 1.0754 1.104
δ = 0.30 Wcor,δ 0.94062 0.9855 1.095 0.94886 0.9643 0.946
Wδ 1.03363 1.1026 1.228 1.01472 1.0400 1.025
δ = 0.40 Wcor,δ 0.90898 0.8968 0.923 0.94026 0.9457 0.894
Wδ 0.99986 0.9976 1.041 1.00667 1.0146 0.976
R = S = 2000
T 1.00585 1.0156 1.034 1.00851 1.0144 1.032
δ = pi Wcor 1.00007 1.1170 1.368 0.96987 0.9840 1.025
W 1.06733 1.2046 1.475 1.01565 1.0422 1.099
δ = 0.20 Wcor,δ 0.98525 1.0636 1.245 0.96734 0.9793 0.988
Wδ 1.04942 1.1459 1.345 1.01188 1.0290 1.064
δ = 0.30 Wcor,δ 0.95502 0.9889 1.075 0.96125 0.9620 0.990
Wδ 1.01906 1.0649 1.157 1.00730 1.0171 1.032
δ = 0.40 Wcor,δ 0.93863 0.9400 0.973 0.95732 0.9536 0.971
Wδ 1.00167 1.0156 1.052 1.00206 1.0008 1.016
Table 1: Type I error for the three tests for several values of δ, different genetic models, and
different sample sizes. (pi = 0.15)
to a standard normal distribution (concluded from QQ-plots and histograms of the p-values)
and the power-function equals the maximum of the power-functions for T and W . For low
sample sizes and/or low minor allele frequencies at the marker, the null distribution deviates
from the standard normal distribution in just one tail. For all observations in that tail Qˆ < 1
(the test-statistic U equals W ). This was also seen for the test-statistic W and is therefore as
expected. This problem can be easily solved by recalculating the small p-values in the tail by
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permutations.
The observations in the opposite tail all had Qˆ > 1 (U equals T ) and the fit with the standard
normal distribution is good (as expected, since the null distribution for T is standard normal
also if the sample size is low). The results of these simulation studies are not shown in this
paper, because, to our opinion, the results are as expected and do not add much to the paper.
4 Discussion
Several methods have been proposed for selecting markers for follow-up in a case-control associ-
ation study. One of the most popular test is the allele based test that considers the difference of
marker allele frequency among cases and controls. A disadvantage of this test is its preference
for markers with high minor allele frequencies; markers with low minor allele frequency have
less power to be detected than markers with a high minor allele frequency.
In this paper a new allele based association test for finding markers that are associated with
a disease is proposed. The test is model-free and the test-statistic can be computed easily and
fast. Moreover, the asymptotic null distribution of the test-statistic is known what makes the
computations of p-values fast; permutations are not necessary. The power of the test is higher
than for the commonly used test for many genetic models that are of practical interest. For
those models, the lower the minor allele frequency is, the more power is gained by using the new
test. This is mainly caused by the fact that the power of the proposed test is approximately
constant as a function of the marker allele frequency; the proposed test does not favor markers
with a high minor allele frequencies. So, ranking the markers based on their p-values becomes
a more objective way of selecting interesting markers for follow-up studies and, because of its
high power for markers with a low minor allele frequency (compared to the existing test), the
proposed test may reveal interesting regions for follow-up study.
The proposed test-statistic depends on the parameter pi, the prevalence of the disease. This
parameter cannot be estimated based on the data itself, but should be estimated from external
data. For most diseases, population risks are available, for instance from national registries. In
the paper it is shown that the type I error is hardly affected by misspecification of pi, because
under the null hypothesis the parameter (almost) drops out from the test-statistic if the number
of observations is large. In practice, it is quite common to estimate nuisance parameters in
the model based on external data and to assume that these estimated nuisance parameters are
known when performing statistical tests or constructing confidence intervals for the parameter
of interest. The extra uncertainty due to the estimation of these nuisance parameter are often
not taken into account what may lead to wrong type I errors, in general . In [4] the effect on
the type I error for the likelihood ratio test-statistic is studied.
We generalized the model by allowing other values for pi between zero and one. This may
yield higher power for some markers, but the a priori preference for markers with high or low
MAFs is back again. Moreover, by taking values near the boundary (zero or one), the type I
error may increase above acceptable levels. We therefore advice to use pi as first choice. However,
if pi itself is low (near zero) and the sample size is not huge, the type I error may be inflated
if the marker MAF is low. In that case one could decide to impute a higher value for δ in the
denominator of the test-statistic, so δ > pi, to give up some power and lower the number of false
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discoveries. This was seen in the simulation study in this manuscript.
In the derivation of the test-statisticW as well as in the simulation studies we assume that the
alleles at a marker and causal variant are in Hardy-Weinberg equilibrium. However, deviations
from Hardy-Weinberg equilibrium can inflate the chance of a false-positive association ([6]). In
[6] an test-statistic that accounts for deviation from HWE is introduced; an extra term is added
to the variance in the denominator of the test-statistic. Our test-statistic can be adjusted in
a similar way, what makes the type I error of the test robust against deviation from Hardy
Weinberg.
When the Hardy-Weinberg proportions hold in the total population, the allele-based test
T and the Cochran-Armitage Trend test for the additive model are asymptotically equivalent
under the null hypothesis ([1, 15]). Since T and W are also asymptotically equivalent under the
null hypothesis, this also holds for W and the Cochran-Armitage Trend test (CATT). Under the
alternative hypothesis, the power functions differ. Based on a simulation study, [15] show that
the power of the allele-based test T and the CATT for additive models are, nevertheless, very
similar, with a slightly higher power for the allele-based test T under the recessive model and
for the CATT under the dominant model (for genetic models they consider). For the genetic
models for which the test based on W is more powerful than the test based on T , the test based
on W is also more powerful than the CATT.
Another association test is a score test based on a logistic regression model. The score test
statistic equals the CATT ([15]), from which it directly follows from the previous paragraph that
in many interesting settings, the allele-based test W is also more powerful than the score-test
for a logistic regression model.
For some genetic settings the test based on T is more powerful than the test based on W . We
therefore combined the two test-statistics to a test-statistic U that always has an (asymptotic)
power of at least the tests T or U . Although the test-statistic is more complicated now, it still
has asymptotically a standard normal distribution under the null hypothesis and p-values can
be easily obtained.
A part of the missing heritability might be explained by causal variants with a low minor
allele frequency. The test proposed in this paper, may help detecting a part of the undiscovered
causal variants.
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